

Northern Territory of Australia

Medicines, Poisons and Therapeutic Goods Act 2012

**Family Planning Welfare Association NT SSTP
Approval**

I, Paul Burgess, Acting Chief Health Officer:

- (a) under section 254(1) of the Act, approve each Scheduled substance treatment protocol specified in Schedule A;
- (b) under section 254(3) of the Act, state that each Schedule substance treatment protocol specified in Schedule A remains in effect for a period of 2 years on and from the date of this instrument.

Dated 25/11/2024

A/Chief Health Officer

Schedule A

Title	Publication Date	Author
Family Planning Welfare Association NT SSTP	25 November 2024	Medicines and Poisons, Northern Territory Government, Department of Health

Family Planning Welfare Association NT SSTP

Areas Applicable	NT Wide			
Health Professionals authorised by this SSTP	Nurses, Midwives and Aboriginal and Torres Strait Islander Practitioners employed by or contracted to FAMILY PLANNING WELFARE ASSN OF NT INC (ABN 38 812 238 738) trading as Family Planning Welfare Association NT (FPWNT).			
Scheduled Substance(s)	Adrenaline	Mifepristone	Ulipristal	Nomegestrol
	Amoxicillin	Misoprostol	Ethinylloestradiol	Gestodene
	Azithromycin	Nitrofurantoin	Estradiol	Levonorgestrel
	Benzathine Penicillin	Paracetamol	Norethisterone	Medroxyprogesterone
	Ceftriaxone	Podophyllotoxin	Progesterone	
	Cephalexin	Probenecid	Cyproterone	
	Clotrimazole	Salbutamol	Desogestrel	
	Lidocaine	Trimethoprim	Dienogest	
	Methoxyflurane	Valaciclovir	Drospirenone	
	Metronidazole	Xylocaine	Etonogesteral	
Indication, Dose, Route, Frequency	<ul style="list-style-type: none"> Individual substances, or combinations of substances, are to be used according to the indication for which they are being administered as outlined in the "FPWNT Clinical Guidelines" as in force from time to time. Any administration of these substances outside of the approved Guidelines must be under direct instruction of a Medical Practitioner. 			
Contraindications and/or Exclusions*	<ul style="list-style-type: none"> Hypersensitivity or allergy to the individual drug substance or excipients of that formulation of the listed scheduled substances of this protocol. Any contraindications or exclusions as outlined in the individual scheduled substance product information. Any contraindication or exclusions as outlined in FPWNT Clinical Guidelines. 			

Health Professional Accreditation Requirements	<p><u>Nurses and Midwives must:</u></p> <ul style="list-style-type: none"> • Hold registration with the Nursing and Midwifery Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients. • Maintain continuing professional development related to skills and competencies required for delivery of medicines. <p><u>Aboriginal and Torres Strait Islander Health Practitioners must:</u></p> <ul style="list-style-type: none"> • Hold registration with the Aboriginal and Torres Strait Islander Health Practice Board of Australia with no conditions or undertakings which may limit delivery of clinical services directly to patients. • Maintain continuing professional development related to skills and competencies required for delivery of medicines. 		
Chief Health Officer	Signature	Name	Date
	EDOC2024/310957	Adjunct Prof. Paul Burgess	25/11/2024
Period of effect	This SSTP is in force until 25/11/2026 unless revoked earlier		
<p>References: * The drug information provided is to act as a guide to outline the limits of legal dealing with the named scheduled substances. Further information reference should be made to the full manufacturer’s product info and other reliable sources of medicines information. If contraindications or interactions are present refer to medical officer before administration</p>			